Latest Commercialization News

Centaurus Metals has locked in a binding five-year offtake agreement with global giant Glencore for a third of its Jaguar Nickel Project’s output, marking a pivotal step towards commercial production in Brazil.

EcoGraf Limited has signed a non-binding MoU with Taiwan’s Long Time Technology to develop HFfree® purification facilities and expand battery anode operations across South East Asia and Taiwan, aiming to tap into Tier-1 OEM supply chains.

Forrestania Resources has begun mining and delivering ore to Westgold’s Higginsville hub, marking its official transition from explorer to gold producer. The company is also refurbishing its own Lake Johnston facility to establish independent processing capabilities.

Racura Oncology has secured governance approval to launch its Phase 1 HARNESS-1 trial, testing RC220 alongside osimertinib in EGFR-mutated non-small cell lung cancer patients. This milestone sets the stage for a potentially pivotal new approach to overcoming resistance in lung cancer treatment.

ABx Group has announced a breakthrough with its second mixed rare earth carbonate sample from Tasmania’s Deep Leads deposit, boasting higher heavy rare earth content and fewer impurities. This advancement enhances project flexibility and strengthens ABx’s position in the competitive rare earths market.

NH3 Clean Energy has locked in a crucial 15-year water supply agreement with the Water Corporation of WA for its flagship WAH2 clean ammonia project, marking a key step towards its final investment decision.

Calix Limited has successfully completed the first milestone of its ARENA grant for the Zesty Green Iron Demonstration Project, unlocking a $2 million payment and marking a key step forward in its industrial decarbonisation efforts.

Dimerix Limited is set to conduct a blinded statistical review of its pivotal Phase 3 ACTION3 study in March 2026, aiming to confirm the trial remains powered to demonstrate the primary endpoint of proteinuria reduction in FSGS patients.

Syrah Resources has secured an extension to the cure date for an alleged default under its Tesla offtake agreement, pushing the deadline from March to June 2026 as both parties work to resolve outstanding issues.

Telix Pharmaceuticals has resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara®), aiming to advance a novel PET imaging agent for glioma diagnosis. The resubmission addresses prior regulatory concerns with additional data, reinforcing hopes for expedited approval.

EMVision Medical Devices has secured a $3.8 million R&D tax rebate and gained approval to claim rebates on overseas expenditures, strengthening its financial footing as it advances clinical trials for its neurodiagnostic device.

Vection Technologies has secured approximately $4 million in new orders for its Algho AI platform, spanning 10 diverse industry verticals and reinforcing its strong momentum following a record half-year performance.